STOCK TITAN

Relief Therapeut - RLFTY STOCK NEWS

Welcome to our dedicated page for Relief Therapeut news (Ticker: RLFTY), a resource for investors and traders seeking the latest updates and insights on Relief Therapeut stock.

Overview of Relief Therapeutics (RLFTY)

Relief Therapeutics is a commercial‐stage biopharmaceutical company committed to advancing innovative treatment options in select specialty, unmet, and rare diseases. Operating with a focus on conditions such as rare metabolic disorders and dermatological conditions, the company is dedicated to improving therapeutic outcomes through state-of-the-art drug formulation and a robust clinical development pipeline. With proprietary technologies including the TEHCLO™ and Physiomimic™ platforms, Relief Therapeutics develops patient-friendly formulations that enhance treatment adherence, ensuring effective management for complex, chronic conditions.

Core Business Areas and Technological Innovations

The company focuses on three core therapeutic areas: rare skin diseases, rare metabolic disorders, and rare respiratory diseases. Its pipeline includes innovatively formulated treatments such as a highly concentrated liquid formulation for phenylketonuria (PKU) designed to reduce the medication volume, thereby improving patient compliance. Additionally, Relief Therapeutics is advancing solutions for conditions like epidermolysis bullosa (EB) by employing a stabilized hypochlorous acid solution, which not only promotes wound healing but also effectively manages infections by targeting pathogenic bacteria while preserving beneficial microbiome diversity.

Clinical Development and Research Rigor

Relief Therapeutics maintains a rigorous clinical development strategy characterized by multiple proof-of-concept and pilot trials. The results from these studies have shown promising bioequivalence and patient compliance parameters, enabling more flexible dosing options compared to standard treatments. Each clinical investigation is crafted to address specific treatment challenges, thereby ensuring that the solutions are both innovative and closely aligned with patient needs.

Market Position and Strategic Collaborations

Headquartered in Geneva, the company operates on a global scale, with its shares listed on the SIX Swiss Exchange and quoted on the U.S. OTCQB market. Relief Therapeutics employs a balanced business model that combines marketed, revenue-generating products with a forward-looking clinical development pipeline. Strategic licensing and distribution partnerships further enhance its market presence, allowing the company to leverage both its novel technologies and existing products to meet uncompromised quality and compliance standards required by healthcare providers worldwide.

Competitive Differentiators and Patient-Centric Approach

What sets Relief Therapeutics apart is its commitment to creating formulations that are not only efficacious but also tailored for patient convenience. By reducing the dosage volume and offering flexible administration options, its treatments help mitigate common adherence challenges in rare diseases, particularly those affecting pediatric and multi-age patient populations. The company’s investment in innovative technology, coupled with strategically designed clinical trials, positions it uniquely in a competitive landscape where scientific rigor and patient outcomes are at the forefront.

Industry Terminology and Regulatory Milestones

  • Bioequivalence: Clinical studies comparing the novel formulations with established treatments to ensure similar therapeutic exposures.
  • Proprietary Formulation Technology: Use of patented platforms like TEHCLO™ that underpin the company’s innovative drug delivery mechanisms.
  • Regulatory Submissions: Meticulous planning to achieve pivotal trial results and support potential applications under frameworks such as the 505(b)(2) NDA pathway in the United States.

Overall, Relief Therapeutics demonstrates an unwavering focus on enhancing the quality of life for patients with challenging and rare conditions through a well-orchestrated blend of innovative technology, clinical expertise, and comprehensive regulatory strategy. This detailed approach serves both to inform and to guide financial analysts and healthcare professionals seeking an in-depth understanding of the company’s operations and business model.

Rhea-AI Summary

Relief Therapeutics has filed Amendment No. 4 to its Registration Statement on Form 20-F with the SEC to register as a reporting company under the Securities Exchange Act. This is part of its program to transition its Level 1 ADR to a Level 2 ADR and aims for a potential NASDAQ listing, although no assurance of success is provided. The filing does not involve an offering of securities, and Relief will not receive any proceeds from its current ADR program. The company's focus includes clinical-stage programs and partnerships for drug development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Relief Therapeutics Holding SA reported on July 4, 2022, that the FDA has declined to issue an Emergency Use Authorization (EUA) for aviptadil concerning a subgroup of patients also receiving remdesivir. This decision impacts the company as it collaborates with NRx Pharmaceuticals, whose subsidiary, NeuroRx, is involved with aviptadil's development. Relief is involved in clinical-stage programs aimed at serious unmet medical needs, including various metabolic disorders. The firm has also expanded its pipeline through recent acquisitions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
covid-19
-
Rhea-AI Summary

Relief Therapeutics has filed Amendment No. 3 to its Registration Statement on Form 20-F with the SEC to transition its Level 1 American Depositary Receipt program to a Level 2 program, facilitating a potential listing on NASDAQ. The filing does not generate any proceeds for the company and is part of an ongoing effort to enhance its market presence. The effectiveness of the Registration Statement remains under review, and there is no guarantee of a successful listing. Relief continues focusing on clinical-stage programs, including collaborations for drug development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.32%
Tags
none
Rhea-AI Summary

Relief Therapeutics Holding SA announced that its parent company, NRx Pharmaceuticals, Inc., faced a setback as the FDA denied its application for Breakthrough Therapy designation for aviptadil. This rejection could have significant implications for the drug's further development, particularly in treating serious lung conditions, including COVID-19. Relief maintains its focus on clinical-stage programs and has a collaboration with Acer Therapeutics for developing ACER-001.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.45%
Tags
none
-
Rhea-AI Summary

Relief Therapeutics Holding SA reported that its partner Acer Therapeutics has not received a decision from the FDA on the 505(b)(2) NDA for ACER-001 (sodium phenylbutyrate) aimed at treating urea cycle disorders. The NDA was accepted for review on October 5, 2021, with a PDUFA target action date of June 5, 2022. Currently, the FDA's review is ongoing without a set target date. Relief and Acer will issue a joint release once the FDA decision is made, impacting the prospects of their development and commercialization agreement for ACER-001.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Relief Therapeutics Holding SA announced the results of its Annual General Meeting (AGM) held on May 31, 2022, with over 85% approval for all proposed resolutions. Key outcomes include the approval of the 2021 financial statements, carrying forward a loss of CHF 29,553,450, and maintaining an authorized share capital of CHF 22,000,000. The AGM also approved maximum compensation of CHF 2,500,000 for the Board and CHF 5,000,000 for the Executive Committee. Re-elections for Board members and auditors were confirmed. This meeting underlines the company's ongoing efforts in its clinical-stage programs and collaborations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Relief Therapeutics provided a corporate update on May 31, 2022, highlighting the discontinuation of the ACTIVE-3b/TESICO trial for COVID-19 due to futility. Despite this, the company is committed to pursuing RLF-100 for various pulmonary indications and initiating new clinical trials. Upcoming catalysts include potential FDA approval for ACER-001 on June 5, 2022, and launching its U.S. commercial operations for PKU GOLIKE. Relief has CHF 31 million in cash to fund operations into 2023 and aims for positive cash flow by late 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.66%
Tags
covid-19
-
Rhea-AI Summary

Relief Therapeutics (OTCQB: RLFTF, RLFTY) announced that its collaboration partner, NRx Pharmaceuticals, reported on May 25, 2022, the Data Safety and Monitoring Board's (DSMB) review of the ACTIV-3b (TESICO) trial data. The DSMB determined that evaluation of aviptadil should cease due to futility after reviewing data from approximately 460 patients with Critical COVID-19 Respiratory Failure. This development raises concerns about the viability of aviptadil for treating this condition. Relief is also involved in the FDA filing of ACER-001, with a decision date set for June 5, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-49.73%
Tags
covid-19
-
Rhea-AI Summary

Relief Therapeutics Holding SA has announced the appointment of Tracy Truong and Kelli Powell as Regional Clinical Specialists for the West and Northeast Regions, effective May 23, 2022. Both specialists bring significant experience in pharmaceutical sales, particularly in rare diseases, having worked for top companies like Alexion and NPS Pharmaceuticals. Their expertise will support the anticipated rollout of PKU GOLIKE and the potential launch of ACER-001 for Urea Cycle Disorders, with a crucial PDUFA date set for June 5, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Relief Therapeutics Holding SA has submitted Amendment No. 2 to its Registration Statement on Form 20-F to the U.S. SEC, aiming to transition its Level 1 American Depositary Receipt (ADR) program to a Level 2 ADR program. This is part of Relief's goal to list its ADRs on the NASDAQ Stock Market. The effectiveness of the Registration Statement and the subsequent NASDAQ listing remain uncertain. Notably, there are no proceeds from this filing as it does not involve a securities offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Relief Therapeut (RLFTY)?

The current stock price of Relief Therapeut (RLFTY) is $3.4 as of April 16, 2025.

What is the market cap of Relief Therapeut (RLFTY)?

The market cap of Relief Therapeut (RLFTY) is approximately 40.1M.

What is Relief Therapeutics' primary business focus?

Relief Therapeutics is dedicated to developing innovative treatment options for select specialty, unmet, and rare diseases. Its focus is on creating patient-friendly formulations that improve adherence and efficacy in challenging clinical areas.

How does Relief Therapeutics generate revenue?

The company generates revenue through a balanced mix of marketed, revenue-generating products and a targeted clinical development pipeline. It also leverages licensing and distribution partnerships to commercialize legacy and innovative products.

What proprietary technologies does the company use?

Relief Therapeutics employs proprietary platforms such as TEHCLO™ and Physiomimic™, which underpin its innovative drug formulation processes. These technologies help in developing formulations that enhance drug bioavailability and patient compliance.

Which therapeutic areas are targeted by Relief Therapeutics?

The company focuses on three core therapeutic areas: rare skin diseases, rare metabolic disorders, and rare respiratory diseases. Its development programs are tailored to address the specific challenges presented by these conditions.

How does the RLF-OD032 formulation improve treatment for PKU patients?

RLF-OD032 is designed as a highly concentrated liquid formulation that significantly reduces the required medication volume compared to existing treatments. This approach enhances patient convenience and adherence, making it a more user-friendly option for PKU management.

What benefits does RLF-TD011 offer for epidermolysis bullosa patients?

RLF-TD011 is a stabilized hypochlorous acid solution that shows promising antimicrobial properties, promoting wound healing by reducing pathogenic bacteria such as Staphylococcus aureus. Clinical trials have shown improvements in wound closure and overall microbiome diversity in EB patients.

What strategic partnerships does Relief Therapeutics engage in?

The company collaborates with various licensing and distribution partners to commercialize its products globally. These strategic alliances help extend market reach and optimize resource allocation across its portfolio.

Where is Relief Therapeutics headquartered and how is it traded?

Relief Therapeutics is headquartered in Geneva, Switzerland. The company is listed on the SIX Swiss Exchange under the symbol RLF and is also quoted on the U.S. OTCQB market under the symbols RLFTF and RLFTY.
Relief Therapeut

OTC:RLFTY

RLFTY Rankings

RLFTY Stock Data

40.13M
9.56M
Biotechnology
Healthcare
Link
Switzerland
Geneva